Articles tagged with B Cell Development
Researchers at Tohoku University have discovered a previously unknown pathway for B-cell development in chickens, bypassing the bursa of Fabricius. The discovery reveals that B cells originate in the bone marrow and migrate to the cecal tonsils, establishing an IgA-mediated intestinal barrier.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers at Garvan Institute of Medical Research discovered how chronic hepatitis C infection leads to autoimmune disease by identifying 'rogue clone' B cells with harmful autoantibodies. The study found that a triad of genetic mutations is required for the autoimmune disease to develop, opening new paths for treatments.
Scientists have discovered how a mutated ASXL1 gene disrupts normal blood cell development, leading to diseases such as clonal hematopoiesis and malignant leukemias. The study reveals that mutated ASXL1 causes heterochromatin dysfunction, silencing genes essential for blood cell maturation.
Researchers have identified a promising new drug, lomonitinib, targeting treatment-resistant acute myeloid leukemia (AML) with FLT-3 mutation. Additionally, they developed a novel compound to target MALT1 protein in chronic lymphocytic leukemia (CLL), aiming to provide better control of the disease.
Pro-B cells, a stage in B cell development, exhibit unusual plasticity when YY1 is knocked out. This enables them to generate T lineage cells, which help B cells produce antibodies. The study published in Genes & Development reveals the potential for regenerative medicine applications.
A team of researchers at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections. The antibodies were found to interact with antigens on the bacterial surface and some act synergistically to neutralize the pathogen.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
A Mayo Clinic study found that people with monoclonal B-cell lymphocytosis (MBL) have a 92% elevated risk of developing melanoma. MBL is a precursor to chronic lymphocytic leukemia and also increases the risk of cancers originating in the lymphatic system and serious infections.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
A study published in PNAS reveals that ETV5 enhances the expression of osteopontin, leading to the differentiation of T cells into follicular helper cells. In SLE patients, disease activity is proportional to ETV5 and osteopontin levels, suggesting a potential therapeutic target for treating lupus.
A Kobe University study finds that a new treatment for neuromyelitis optica spectrum disorder shifts the balance of immune cells, increasing anti-inflammatory signals. The discovery may enable clinicians to determine treatment effectiveness and move towards personalized medicine for autoimmune diseases.
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
Researchers from Osaka University found that Csk inhibits germinal center B cell signaling, decreasing reactive oxygen species production and promoting affinity maturation. This study reveals the crucial role of Csk tyrosine kinase in regulating B cell development.
A study from USC Keck School of Medicine reveals a genetic variant on the IKZF1 gene contributing to increased risk of acute lymphoblastic leukemia among Hispanic/Latino children. The variant increases ALL risk by around 1.4 times and may be linked to Indigenous American ancestry, according to researchers.
A study published in Nature found that the response to hematopoietic insults differs across the skeleton, with certain bones specialized to respond to specific stresses. The research uses confocal imaging microscopy to count different cell types and provides new insights into blood cell production, potentially leading to improved treat...
Researchers have identified two new proteins critical for B-cell acute lymphoblastic leukaemia development, leading to potential treatments and a clinical trial. The study's findings could lead to the development of targeted therapies for the aggressive disease.
Researchers at the University of Freiburg discovered that defective signalling pathways play a decisive role in immune cell development, leading to problems with B cell maturation and function. This finding opens up new therapeutic approaches for autoimmune diseases like ALPS.
Researchers have discovered that immune cells play a crucial role in directing the growth of human lung tissue during development, revolutionizing our understanding of early lung development. The findings also suggest that early immune disturbances could manifest as pediatric lung disease.
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
Researchers at La Jolla Institute for Immunology and Massachusetts General Hospital mapped the genome to understand how IKAROS controls healthy B cell development. They found that IKAROS solves a big problem in B cell development by bringing together far-away genes through looping, leading to proper expression and antibody production.
Scientists have found that lung-resident memory B cells, critical for pulmonary immunity, require interferon-gamma produced by T follicular helper cells to differentiate. These long-lived immune cells migrate to the lungs from draining lymph nodes and lie in wait to react quickly to future infections.
A recent study found elevated TonEBP expression in patients with lupus nephritis, correlating with inflammatory cytokines and kidney damage. Suppressing TonEBP was shown to halt lupus progression and mitigate kidney damage in animal models.
Researchers at the Babraham Institute have discovered that the 3D organisation of DNA in B cells allows for genes far away from each other to come together during antibody generation. This finding has implications for understanding why antibody diversity declines with age and suggests potential interventions.
The GEMINI blood test uses machine learning to identify cancer-causing mutations in single molecules of cell-free DNA. The test detected over 90% of lung cancers, including stage I and II cases, in a proof-of-concept study published in Nature Genetics.
A new study reveals that breast milk contains a unique set of antibodies passed from mom to baby, which can vary significantly between mothers. This variability may explain why some infants develop life-threatening diseases like NEC, while others do not.
Researchers investigate MCL-1i-induced Mcl-1 protein accumulation and its implications in B-cell malignancies. The study reveals a complex mechanism contributing to MCL-1 protein stability upon treatment with MCL-1 inhibitors.
Researchers have developed an automated calling algorithm for determining B and T cell clonality from NGS data with greater sensitivity than previous models. The new model increases the assay's sensitivity in detecting clonality, allowing for more accurate diagnosis and monitoring of lymphoproliferative disorders.
A protein called PI3K plays a crucial role in immune cell function, and genetic variations disrupting its signalling have been identified as the root cause of two immunodeficiency disorders. The study reveals how minor disruptions in immune cell signalling can lead to immune deficiency or dysfunction.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
Researchers at Scripps Research, IAVI, Fred Hutch, and VRC publish study data in Science, revealing a stepwise approach to producing antibodies capable of targeting wide range of HIV variants. The Phase 1 trial shows favorable safety profile and induces targeted response in 97% of vaccinated individuals.
Researchers found that a substantial portion of adult B cells develop in the first days of life after birth, potentially influencing long-term immune health and susceptibility to disease. This discovery provides new insights into how microbial exposure and infections shape the human immune system.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
A UT Southwestern study reveals that RNA exosomes are crucial for B cell development, which is critical for the immune system's ability to fight infection. The findings also explain why patients with a rare disease associated with RNA exosome deficiency experience immunodeficiency and recurrent infections.
Researchers found that MS patients treated with Rituximab who have higher B cell counts of 40/µL or more develop protective levels of antibodies after vaccination. This suggests that measuring B cell level before vaccination is crucial for increasing the chance of a positive response.
The American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, recognizing distinguished scientists who have propelled innovation and progress against cancer. The 2022 class consists of 33 luminaries from various scientific disciplines.
Researchers will focus on understanding the disease, identifying B cell characteristics and plasma cells that create attacking antibodies. The study aims to enhance knowledge of SLE pathogenesis and differences in clinical manifestations, outcomes, and therapeutic responses.
A study by Weill Cornell Medicine identified Oct2 as the key determinant of B-cell humoral immune response, suggesting that the destiny of antibody-producing cells is predetermined. This discovery may lead to new insights into tissue development and cancer development.
Researchers discovered a nanomaterial that boosts antibody production while minimizing inflammation, opening up new possibilities for vaccine development. The 'micelle' scaffolds can be used to generate laboratory-scale quantities of therapeutic antibodies against real-world pathogens.
Researchers found that COVID-19 patients who experience cytokine storms have a disrupted immune response, leading to the formation of few germinal centers and thus preventing durable immunity. Although some neutralizing antibodies are produced, they lack long-term memory, allowing for repeated infections with the same virus.
Researchers at the University of Pennsylvania discovered a dynamic two-step mechanism in female immune cells to regulate X chromosome inactivation. B cells regain X-chromosome markers during activation through the transcription factor YY1, leading to increased gene expression related to immunity.
Belgian scientists discovered protein Taok3 plays a key role in B cell development, leading to new molecular therapies for genetic conditions, asthma and diabetes. Mice genetically lacking Taok3 developed fewer type B immune cells, making them more susceptible to bacterial infections.
Researchers at The Scripps Research Institute (TSRI) found that members of a cluster of microRNAs work together throughout the stages of immune cell generation. Different miRNAs dominate different stages as disease-targeting immune cells develop, guiding the development of therapies against autoimmune diseases.
Researchers discovered that B cells rely on RNA binding proteins ZFP36L1 and ZFP36L2 to induce quiescence, allowing them to 'rest up' between developmental events. This mechanism is crucial for proper B cell development, as seen in mice where a 98% reduction of mature B cells was observed when these proteins were absent.
Scientists have created a detailed map of human B cell development at the single-cell level, improving research capabilities and identifying rare aberrations that lead to disease. The approach will guide regenerative medicine and help understand complex developmental processes.
Melbourne scientists found that the immune system eliminates potentially cancerous immune B cells on a daily basis. This discovery could lead to an early-warning test identifying patients at high risk of developing B-cell lymphomas.
Researchers found that CVID patients with a single altered TACI allele maintain some residual B cell responsiveness, promoting autoantibody development. In contrast, individuals with two mutated copies of TACI have complete impairment of B cell responses, likely preventing autoimmunity.
A team of IRCM researchers identified a new regulator, Miz-1, essential for the proper development and maturation of B cells. The discovery highlights the importance of the IL-7 signaling pathway for B-cell survival and maturation.
B cells in every cell carry genes necessary to function, but only a small proportion matures into immune-system cells. Two chromatin remodeling complexes work in opposing directions to control epigenetic changes allowing for B-cell development.
A study led by Nina Luning Prak found a lower level of antibody editing in mice and human blood samples from patients with lupus and type 1 diabetes. This suggests that not all autoimmunity is caused by errors in editing, requiring a targeted approach for treatment.
Developing B cells produce the antibody-altering protein AID, which directs and strengthens their response to disease pathogens. This discovery may offer new research directions for understanding autoimmunity and other diseases.
A new study reveals how protein Yin Yang 1 regulates early B cell development, a crucial step in the immune system. The research demonstrates that YY1 plays a key role in controlling variable segment recombination, a process essential for B cell differentiation.
The NIH-funded program will bring together researchers from the Center for Biomedical Inventions and the Touchstone Diabetes Center to develop novel therapies for type II diabetes. Researchers aim to translate basic science into medical therapy, exploring new approaches in treatment and delivery methods.
Researchers demonstrate that different concentrations of transcription factor PU.1 control blood cell progenitor development into B lymphocytes or macrophages, two distinct types of white blood cells. High levels of PU.1 block B cell development and promote macrophage formation.
Scientists discovered that a specific protein controls the developmental destiny of white blood cells. Increasing or decreasing this protein's levels can direct the cells' fate, raising hopes for new therapies.
A team of scientists has discovered that a lack of the B cell linker protein (BLNK) is responsible for an immunodeficiency in mice and a young man with recurring bacterial infections. The study reveals that BLNK plays a crucial role in B lymphocyte development, leading to impaired immune function.